Related Experiment Video
Updated: Aug 11, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Drug insight: Use of docetaxel in prostate and urothelial cancers
Niklas J Mackler1, Kenneth J Pienta
1University of Michigan, Ann Arbour, MI, USA.
Abstract:
Taxanes have emerged as a potent class of chemotherapeutic agents in many malignancies, with two taxanes now in clinical use. Their mechanism of action against tumor cells is by alteration of microtubule dynamics, which causes cell-cycle arrest during mitosis. Docetaxel binds to the microtubules with a higher affinity than paclitaxel, and over a broader range of cell-cycle activities. It has also been shown to promote apoptosis via BCL2 phosphorylation. In hormone-refractory prostate cancer, docetaxel has been studied as both a single agent and in combination with estramustine, and in different treatment schedules, with demonstrated efficacy. Two phase III trials have confirmed a survival benefit, making docetaxel the first chemotherapy agent with proven efficacy against prostate cancer. In urothelial cancer, docetaxel has demonstrated activity and has been investigated as a single agent and in combination regimens. A phase III trial comparing docetaxel and cisplatin to methotrexate, vinblastine, doxorubicin, and cisplatin was inferior when evaluating response rates and overall survival. More recent phase II trials combining docetaxel with two additional agents have shown promise, but confirmatory trials are needed.
Insights
Docetaxel, a taxane chemotherapy, effectively treats hormone-refractory prostate cancer and shows promise in urothelial cancer. It works by disrupting microtubule dynamics, leading to cancer cell death and improved survival rates.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Taxanes are crucial chemotherapeutic agents impacting microtubule dynamics for cancer treatment.
- Docetaxel exhibits higher binding affinity to microtubules than paclitaxel, influencing cell-cycle arrest and apoptosis.
- Docetaxel has demonstrated efficacy in hormone-refractory prostate cancer and urothelial cancer.
Purpose of the Study:
- To review the efficacy and mechanism of action of docetaxel in various malignancies.
- To highlight docetaxel's role in hormone-refractory prostate cancer and urothelial cancer treatment.
Main Methods:
- Review of clinical trials and studies on docetaxel's mechanism of action.
- Analysis of docetaxel's efficacy as a single agent and in combination therapies.
- Evaluation of docetaxel's impact on survival rates and response in prostate and urothelial cancers.
Main Results:
- Docetaxel is the first chemotherapy agent proven to improve survival in prostate cancer.
- Docetaxel demonstrated efficacy in hormone-refractory prostate cancer, both alone and with estramustine.
- While docetaxel showed activity in urothelial cancer, combination regimens require further confirmatory trials.
Conclusions:
- Docetaxel is a vital chemotherapeutic agent with proven survival benefits in prostate cancer.
- Further research is needed to confirm the efficacy of novel docetaxel combination regimens in urothelial cancer.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...